NLRP3 Susceptible Gene Polymorphisms in Patients with Primary Gouty Arthritis and Hyperuricemia

Table 2

The association between the risk of GA and the genetic polymorphisms.

SNP	WT Ho/ Ht/ VR Ho			Codominant model					Dominant model			Recessive model			VR allele vs. WT allele
				VR Ho vs. WT Ho		Ht vs. WT Ho
	Control	GA	C_HWE	P	OR (95% CI)	P	OR (95% CI)	AIC	P	OR (95% CI)	AIC	P	OR (95% CI)	AIC	P	OR (95% CI)
rs10754558(CC/CG/GG)	132/266/109	100/158/56	0.29	0.064	0.68 (0.45-1.03)	0.14	0.78 (0.57-1.09)	1094.6	0.074	0.75 (0.55-1.03)	1093.1	0.2	0.79 (0.55-1.13)	1094.7	0.056	0.82 (0.67-1.01)
rs35829419(CC/CA/AA)	503/4/0	313/1/0	1			0.38	0.40 (0.04-3.61)	1095.6
rs3738448(GG/GT/TT)	325/165/17	204/98/11	0.57	0.94	1.03 (0.47-2.25)	0.72	0.95 (0.70-1.28)	1096.3	0.75	0.95 (0.71-1.28)	1094.3	0.9	1.05 (0.49-2.27)	1094.4	0.82	0.97 (0.75-1.25)
rs3806268(AA/AG/GG)	124/265/117	98/136/75	0.33	0.3	0.81 (0.55-1.20)	0.012	0.65 (0.46-0.91)	1081.3	0.026	0.70 (0.51-0.96)	1080.8	0.71	1.07 (0.76-1.49)	1085.6	0.24	0.89 (0.73-1.08)
rs7525979(CC/CT/TT)	325/165/17	211/92/11	0.57	0.99	1.00 (0.46-2.17)	0.33	0.86 (0.63-1.17)	1097.4	0.36	0.87 (0.65-1.17)	1095.5	0.91	1.05 (0.48-2.26)	1096.3	0.46	0.91 (0.70-1.17)

OR: odds ratio; VR: variant; WT: wild-type; Ht: heterozygote; VR Ho: variant homozygote; WT Ho: wide-type homozygote.